Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2091114467', 'doi': 'https://doi.org/10.1021/jm401326j', 'title': 'Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of <i>Mycobacterium tuberculosis</i> InhA', 'display_name': 'Encoded Library Technology as a Source of Hits for the Discovery and Lead Optimization of a Potent and Selective Class of Bactericidal Direct Inhibitors of <i>Mycobacterium tuberculosis</i> InhA', 'publication_year': 2014, 'publication_date': '2014-01-22', 'ids': {'openalex': 'https://openalex.org/W2091114467', 'doi': 'https://doi.org/10.1021/jm401326j', 'mag': '2091114467', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/24450589'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1021/jm401326j', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S162030435', 'display_name': 'Journal of Medicinal Chemistry', 'issn_l': '0022-2623', 'issn': ['0022-2623', '1520-4804'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320006', 'host_organization_name': 'American Chemical Society', 'host_organization_lineage': ['https://openalex.org/P4310320006'], 'host_organization_lineage_names': ['American Chemical Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5010951795', 'display_name': 'Lourdes Encinas', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Lourdes Encinas', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5071887472', 'display_name': 'Heather P. O’Keefe', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Heather O’Keefe', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5086635331', 'display_name': 'Margarete Neu', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I188950975', 'display_name': 'GlaxoSmithKline (United Kingdom)', 'ror': 'https://ror.org/01xsqw823', 'country_code': 'GB', 'type': 'company', 'lineage': ['https://openalex.org/I188950975']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Margarete Neu', 'raw_affiliation_strings': ['Computational and Structural Chemistry, Platform Technology & Science, GlaxoSmithKline, Stevenage SG1 2NY, Hertfordshire, U.K.'], 'affiliations': [{'raw_affiliation_string': 'Computational and Structural Chemistry, Platform Technology & Science, GlaxoSmithKline, Stevenage SG1 2NY, Hertfordshire, U.K.', 'institution_ids': ['https://openalex.org/I188950975']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5017262949', 'display_name': 'Modesto J. Remuiñán', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Modesto J. Remuiñán', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5010326556', 'display_name': 'Amish Patel', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Amish M. Patel', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5061324782', 'display_name': 'Ana Guardia', 'orcid': 'https://orcid.org/0000-0001-9532-9850'}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Ana Guardia', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5017621829', 'display_name': 'Christopher P. Davie', 'orcid': 'https://orcid.org/0000-0002-9049-4352'}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Christopher P. Davie', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5027119404', 'display_name': 'Natalia Pérez Macías', 'orcid': 'https://orcid.org/0000-0002-9216-8438'}, 'institutions': [{'id': 'https://openalex.org/I4210121842', 'display_name': 'Instituto de Química Médica', 'ror': 'https://ror.org/02vznxv75', 'country_code': 'ES', 'type': 'facility', 'lineage': ['https://openalex.org/I134820265', 'https://openalex.org/I4210121842']}, {'id': 'https://openalex.org/I134820265', 'display_name': 'Consejo Superior de Investigaciones Científicas', 'ror': 'https://ror.org/02gfc7t72', 'country_code': 'ES', 'type': 'government', 'lineage': ['https://openalex.org/I134820265']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Natalia Pérez-Macías', 'raw_affiliation_strings': ['Instituto de Química\rMédica, Consejo Superior de Investigaciones Científicas\r(CSIC), Juan de la Cierva 3, 28006 Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Instituto de Química\rMédica, Consejo Superior de Investigaciones Científicas\r(CSIC), Juan de la Cierva 3, 28006 Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210121842', 'https://openalex.org/I134820265']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5004721352', 'display_name': 'Hongfang Yang', 'orcid': 'https://orcid.org/0000-0002-4216-1190'}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Hongfang Yang', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5063907103', 'display_name': 'M.A. Convery', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I188950975', 'display_name': 'GlaxoSmithKline (United Kingdom)', 'ror': 'https://ror.org/01xsqw823', 'country_code': 'GB', 'type': 'company', 'lineage': ['https://openalex.org/I188950975']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Maire A. Convery', 'raw_affiliation_strings': ['Computational and Structural Chemistry, Platform Technology & Science, GlaxoSmithKline, Stevenage SG1 2NY, Hertfordshire, U.K.'], 'affiliations': [{'raw_affiliation_string': 'Computational and Structural Chemistry, Platform Technology & Science, GlaxoSmithKline, Stevenage SG1 2NY, Hertfordshire, U.K.', 'institution_ids': ['https://openalex.org/I188950975']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5069735970', 'display_name': 'Jeffrey A. Messer', 'orcid': 'https://orcid.org/0000-0001-6636-9642'}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Jeff A. Messer', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5009433918', 'display_name': 'Esther Pérez‐Herrán', 'orcid': 'https://orcid.org/0000-0002-4464-9528'}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Esther Pérez-Herrán', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5080918750', 'display_name': 'Paolo A. Centrella', 'orcid': None}, 'institutions': [], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Paolo A. Centrella', 'raw_affiliation_strings': ['X-Chem Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States'], 'affiliations': [{'raw_affiliation_string': 'X-Chem Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5049895976', 'display_name': 'Daniel Álvarez-Gómez', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Daniel Álvarez-Gómez', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5083278176', 'display_name': 'Matthew Clark', 'orcid': 'https://orcid.org/0000-0002-9348-3528'}, 'institutions': [], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Matthew A. Clark', 'raw_affiliation_strings': ['X-Chem Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States'], 'affiliations': [{'raw_affiliation_string': 'X-Chem Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5015816473', 'display_name': 'Sophie Huss', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Sophie Huss', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5013318442', 'display_name': 'Gary O’Donovan', 'orcid': 'https://orcid.org/0000-0002-8811-9094'}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Gary K. O’Donovan', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5045800044', 'display_name': 'Fátima Ortega-Muro', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Fátima Ortega-Muro', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5050881692', 'display_name': 'William McDowell', 'orcid': 'https://orcid.org/0000-0002-4893-9784'}, 'institutions': [{'id': 'https://openalex.org/I188950975', 'display_name': 'GlaxoSmithKline (United Kingdom)', 'ror': 'https://ror.org/01xsqw823', 'country_code': 'GB', 'type': 'company', 'lineage': ['https://openalex.org/I188950975']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'William McDowell', 'raw_affiliation_strings': ['Biological Reagent and Assay Development, Platform Technology & Science, GlaxoSmithKline, Stevenage SG1 2NY, Hertfordshire, U.K.'], 'affiliations': [{'raw_affiliation_string': 'Biological Reagent and Assay Development, Platform Technology & Science, GlaxoSmithKline, Stevenage SG1 2NY, Hertfordshire, U.K.', 'institution_ids': ['https://openalex.org/I188950975']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5057594962', 'display_name': 'Pablo Castañeda', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Pablo Castañeda', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5005867783', 'display_name': 'Christopher C. Arico-Muendel', 'orcid': 'https://orcid.org/0000-0001-6079-2159'}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Christopher C. Arico-Muendel', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5037537967', 'display_name': 'Stane Pajk', 'orcid': 'https://orcid.org/0000-0002-9496-5879'}, 'institutions': [{'id': 'https://openalex.org/I153976015', 'display_name': 'University of Ljubljana', 'ror': 'https://ror.org/05njb9z20', 'country_code': 'SI', 'type': 'education', 'lineage': ['https://openalex.org/I153976015']}], 'countries': ['SI'], 'is_corresponding': False, 'raw_author_name': 'Stane Pajk', 'raw_affiliation_strings': ['Faculty\rof Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia'], 'affiliations': [{'raw_affiliation_string': 'Faculty\rof Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia', 'institution_ids': ['https://openalex.org/I153976015']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5013412608', 'display_name': 'Joaquı́n Rullas', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Joaquín Rullás', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5020714760', 'display_name': 'Íñigo Angulo-Barturen', 'orcid': 'https://orcid.org/0000-0002-8800-8132'}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Iñigo Angulo-Barturen', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5081114251', 'display_name': 'Emilio Álvarez-Ruíz', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Emilio Álvarez-Ruíz', 'raw_affiliation_strings': ['Centro\rde Investigación Básica, GlaxoSmithKline, 28760 Tres Cantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Centro\rde Investigación Básica, GlaxoSmithKline, 28760 Tres Cantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5040757128', 'display_name': 'Alfonso Mendoza-Losana', 'orcid': 'https://orcid.org/0000-0003-2493-4118'}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Alfonso Mendoza-Losana', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5043335430', 'display_name': 'Lluís Ballell', 'orcid': 'https://orcid.org/0000-0002-3029-1860'}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Lluís Ballell Pages', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5065835759', 'display_name': 'Julia Castro‐Pichel', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210151147', 'display_name': 'GlaxoSmithKline (Spain)', 'ror': 'https://ror.org/049nnjd96', 'country_code': 'ES', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210151147']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Julia Castro-Pichel', 'raw_affiliation_strings': ['Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': 'Diseases of the\rDeveloping World, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo\rOchoa 2, 28760 Tres\rCantos, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210151147']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5025624562', 'display_name': 'Ghotas Evindar', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210114143', 'display_name': 'GlaxoSmithKline (United States)', 'ror': 'https://ror.org/025vn3989', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188950975', 'https://openalex.org/I4210114143']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Ghotas Evindar', 'raw_affiliation_strings': ['ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States'], 'affiliations': [{'raw_affiliation_string': 'ELT Boston, Platform Technology & Science, GlaxoSmithKline, Waltham, Massachusetts 02451, United States', 'institution_ids': ['https://openalex.org/I4210114143']}]}], 'institution_assertions': [], 'countries_distinct_count': 4, 'institutions_distinct_count': 6, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 9.951, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 107, 'citation_normalized_percentile': {'value': 0.999924, 'is_in_top_1_percent': True, 'is_in_top_10_percent': True}, 'cited_by_percentile_year': {'min': 98, 'max': 99}, 'biblio': {'volume': '57', 'issue': '4', 'first_page': '1276', 'last_page': '1288'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10038', 'display_name': 'Tuberculosis', 'score': 0.999, 'subfield': {'id': 'https://openalex.org/subfields/2725', 'display_name': 'Infectious Diseases'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10038', 'display_name': 'Tuberculosis', 'score': 0.999, 'subfield': {'id': 'https://openalex.org/subfields/2725', 'display_name': 'Infectious Diseases'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10211', 'display_name': 'Computational Methods in Drug Discovery', 'score': 0.9975, 'subfield': {'id': 'https://openalex.org/subfields/1703', 'display_name': 'Computational Theory and Mathematics'}, 'field': {'id': 'https://openalex.org/fields/17', 'display_name': 'Computer Science'}, 'domain': {'id': 'https://openalex.org/domains/3', 'display_name': 'Physical Sciences'}}, {'id': 'https://openalex.org/T12827', 'display_name': 'Nucleotide Metabolism and Enzyme Regulation', 'score': 0.9908, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/inha', 'display_name': 'INHA', 'score': 0.99498713}, {'id': 'https://openalex.org/keywords/drug-target-identification', 'display_name': 'Drug Target Identification', 'score': 0.56476}], 'concepts': [{'id': 'https://openalex.org/C2780687663', 'wikidata': 'https://www.wikidata.org/wiki/Q18027924', 'display_name': 'INHA', 'level': 4, 'score': 0.99498713}, {'id': 'https://openalex.org/C2777975735', 'wikidata': 'https://www.wikidata.org/wiki/Q130971', 'display_name': 'Mycobacterium tuberculosis', 'level': 3, 'score': 0.8503977}, {'id': 'https://openalex.org/C57992300', 'wikidata': 'https://www.wikidata.org/wiki/Q2066956', 'display_name': 'Potency', 'level': 3, 'score': 0.77354395}, {'id': 'https://openalex.org/C2776967927', 'wikidata': 'https://www.wikidata.org/wiki/Q423169', 'display_name': 'Isoniazid', 'level': 3, 'score': 0.69654644}, {'id': 'https://openalex.org/C185592680', 'wikidata': 'https://www.wikidata.org/wiki/Q2329', 'display_name': 'Chemistry', 'level': 0, 'score': 0.64368916}, {'id': 'https://openalex.org/C2781069245', 'wikidata': 'https://www.wikidata.org/wiki/Q12204', 'display_name': 'Tuberculosis', 'level': 2, 'score': 0.63176584}, {'id': 'https://openalex.org/C74187038', 'wikidata': 'https://www.wikidata.org/wiki/Q1418791', 'display_name': 'Drug discovery', 'level': 2, 'score': 0.53464574}, {'id': 'https://openalex.org/C207001950', 'wikidata': 'https://www.wikidata.org/wiki/Q141124', 'display_name': 'In vivo', 'level': 2, 'score': 0.41644967}, {'id': 'https://openalex.org/C134651460', 'wikidata': 'https://www.wikidata.org/wiki/Q3100717', 'display_name': 'Reductase', 'level': 3, 'score': 0.41202593}, {'id': 'https://openalex.org/C89423630', 'wikidata': 'https://www.wikidata.org/wiki/Q7193', 'display_name': 'Microbiology', 'level': 1, 'score': 0.3823883}, {'id': 'https://openalex.org/C181199279', 'wikidata': 'https://www.wikidata.org/wiki/Q8047', 'display_name': 'Enzyme', 'level': 2, 'score': 0.37521717}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.35495478}, {'id': 'https://openalex.org/C55493867', 'wikidata': 'https://www.wikidata.org/wiki/Q7094', 'display_name': 'Biochemistry', 'level': 1, 'score': 0.33330464}, {'id': 'https://openalex.org/C202751555', 'wikidata': 'https://www.wikidata.org/wiki/Q221681', 'display_name': 'In vitro', 'level': 2, 'score': 0.22056812}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.15911913}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.13085783}, {'id': 'https://openalex.org/C150903083', 'wikidata': 'https://www.wikidata.org/wiki/Q7108', 'display_name': 'Biotechnology', 'level': 1, 'score': 0.07735917}, {'id': 'https://openalex.org/C142724271', 'wikidata': 'https://www.wikidata.org/wiki/Q7208', 'display_name': 'Pathology', 'level': 1, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D000995', 'descriptor_name': 'Antitubercular Agents', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': True}, {'descriptor_ui': 'D001426', 'descriptor_name': 'Bacterial Proteins', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': True}, {'descriptor_ui': 'D055808', 'descriptor_name': 'Drug Discovery', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}, {'descriptor_ui': 'D009169', 'descriptor_name': 'Mycobacterium tuberculosis', 'qualifier_ui': 'Q000187', 'qualifier_name': 'drug effects', 'is_major_topic': True}, {'descriptor_ui': 'D010088', 'descriptor_name': 'Oxidoreductases', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': True}, {'descriptor_ui': 'D000995', 'descriptor_name': 'Antitubercular Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001426', 'descriptor_name': 'Bacterial Proteins', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009682', 'descriptor_name': 'Magnetic Resonance Spectroscopy', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008826', 'descriptor_name': 'Microbial Sensitivity Tests', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009169', 'descriptor_name': 'Mycobacterium tuberculosis', 'qualifier_ui': 'Q000378', 'qualifier_name': 'metabolism', 'is_major_topic': False}, {'descriptor_ui': 'D009169', 'descriptor_name': 'Mycobacterium tuberculosis', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D010088', 'descriptor_name': 'Oxidoreductases', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D021241', 'descriptor_name': 'Spectrometry, Mass, Electrospray Ionization', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1021/jm401326j', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S162030435', 'display_name': 'Journal of Medicinal Chemistry', 'issn_l': '0022-2623', 'issn': ['0022-2623', '1520-4804'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320006', 'host_organization_name': 'American Chemical Society', 'host_organization_lineage': ['https://openalex.org/P4310320006'], 'host_organization_lineage_names': ['American Chemical Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/24450589', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.81}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 37, 'referenced_works': ['https://openalex.org/W1968753037', 'https://openalex.org/W1970360817', 'https://openalex.org/W1973725396', 'https://openalex.org/W1974154451', 'https://openalex.org/W1982542062', 'https://openalex.org/W2004450236', 'https://openalex.org/W2008525757', 'https://openalex.org/W2014321835', 'https://openalex.org/W2045731972', 'https://openalex.org/W2051960831', 'https://openalex.org/W2060757367', 'https://openalex.org/W2062458432', 'https://openalex.org/W2063618543', 'https://openalex.org/W2063953766', 'https://openalex.org/W2064292547', 'https://openalex.org/W2064943876', 'https://openalex.org/W2069506489', 'https://openalex.org/W2075000963', 'https://openalex.org/W2076415129', 'https://openalex.org/W2079288441', 'https://openalex.org/W2080561646', 'https://openalex.org/W2089656772', 'https://openalex.org/W2091508078', 'https://openalex.org/W2107851387', 'https://openalex.org/W2115132031', 'https://openalex.org/W2117610468', 'https://openalex.org/W2124243126', 'https://openalex.org/W2127073449', 'https://openalex.org/W2127258416', 'https://openalex.org/W2132295452', 'https://openalex.org/W2135732933', 'https://openalex.org/W2142907906', 'https://openalex.org/W2155451228', 'https://openalex.org/W2157196779', 'https://openalex.org/W2161133462', 'https://openalex.org/W2162689645', 'https://openalex.org/W54600962'], 'related_works': ['https://openalex.org/W4387120057', 'https://openalex.org/W3043092866', 'https://openalex.org/W2972610691', 'https://openalex.org/W2794372577', 'https://openalex.org/W2510488826', 'https://openalex.org/W2387194587', 'https://openalex.org/W2347497205', 'https://openalex.org/W2124243126', 'https://openalex.org/W1999305483', 'https://openalex.org/W1480938961'], 'abstract_inverted_index': {'Tuberculosis': [0], '(TB)': [1], 'is': [2, 24], 'one': [3], 'of': [4, 27, 62, 71, 103, 111], 'the': [5, 18, 25, 28, 63, 69, 91, 94, 100, 109, 112, 119], "world's": [6], 'oldest': [7], 'and': [8, 39, 108], 'deadliest': [9], 'diseases,': [10], 'killing': [11], 'a': [12, 104], 'person': [13], 'every': [14], '20': [15], 's.': [16], 'InhA,': [17], 'enoyl-ACP': [19], 'reductase': [20], 'from': [21], 'Mycobacterium': [22], 'tuberculosis,': [23], 'target': [26, 37], 'frontline': [29], 'antitubercular': [30, 86], 'drug': [31], 'isoniazid': [32], '(INH).': [33], 'Compounds': [34], 'that': [35], 'directly': [36], 'InhA': [38, 73], 'do': [40], 'not': [41], 'require': [42], 'activation': [43], 'by': [44, 56], 'mycobacterial': [45], 'catalase': [46], 'peroxidase': [47], 'KatG': [48], 'are': [49], 'promising': [50], 'candidates': [51], 'for': [52, 97], 'treating': [53], 'infections': [54], 'caused': [55], 'INH': [57], 'resistant': [58], 'strains.': [59], 'The': [60], 'application': [61], 'encoded': [64], 'library': [65], 'technology': [66], '(ELT)': [67], 'to': [68], 'discovery': [70], 'direct': [72], 'inhibitors': [74], 'yielded': [75], 'compound': [76, 121], '7': [77], 'endowed': [78], 'with': [79, 84, 118], 'good': [80], 'enzymatic': [81], 'potency': [82, 98], 'but': [83], 'low': [85], 'potency.': [87], 'This': [88], 'work': [89], 'reports': [90], 'hit': [92], 'identification,': [93], 'selected': [95], 'strategy': [96], 'optimization,': [99], 'structure–activity': [101], 'relationships': [102], 'hundred': [105], 'analogues': [106], 'synthesized,': [107], 'results': [110], 'in': [113], 'vivo': [114], 'efficacy': [115], 'studies': [116], 'performed': [117], 'lead': [120], '65.': [122]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2091114467', 'counts_by_year': [{'year': 2024, 'cited_by_count': 7}, {'year': 2023, 'cited_by_count': 8}, {'year': 2022, 'cited_by_count': 6}, {'year': 2021, 'cited_by_count': 5}, {'year': 2020, 'cited_by_count': 10}, {'year': 2019, 'cited_by_count': 8}, {'year': 2018, 'cited_by_count': 9}, {'year': 2017, 'cited_by_count': 11}, {'year': 2016, 'cited_by_count': 17}, {'year': 2015, 'cited_by_count': 18}, {'year': 2014, 'cited_by_count': 8}], 'updated_date': '2024-09-20T00:41:30.877477', 'created_date': '2016-06-24'}